September 20, 2017 3:15 PM ET


Company Overview of CSL Behring LLC

Company Overview

CSL Behring LLC, a biopharmaceutical company, engages in the research, development, manufacture, and marketing of protein-based therapies for the treatment of serious and rare conditions worldwide. It offers bleeding disorder, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies. The company also operates a plasma collection network. Its therapies are indicated for the treatment of coagulation disorders, including hemophilia and von Willebrand disease; primary immune deficiencies; neurological conditions; inherited respiratory diseases; hereditary angioedema; and cardiac surgery, organ transplantation, burn treatment, and hemolytic disease preve...

1020 First Avenue

P.O. Box 61501

King of Prussia, PA 19406-0901

United States

Founded in 2000





Key Executives for CSL Behring LLC

Chief Executive Officer and Managing Director
Age: 60
Chief Financial Officer
Age: 51
Executive Vice President of Global Commercial Operations
Age: 58
Chief Scientific Officer and R&D Director
Age: 62
Compensation as of Fiscal Year 2017.

CSL Behring LLC Key Developments

Health Canada Approves CSL Behring's Berinert® by for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients

CSL Behring announced that on March 31, 2017 Berinert (C1 Esterase Inhibitor, Human) was approved by Heath Canada for Pediatric Hereditary Angioedema (HAE). Berinert is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema of moderate to severe intensity in pediatric and adult patients. The safety and efficacy of Berinert for prophylactic therapy has not been established.

CSL Behring LLC Presents at Annual Medical Science Liaison Society Conference, Sep-05-2017

CSL Behring LLC Presents at Annual Medical Science Liaison Society Conference, Sep-05-2017 . Venue: Venetian Hotel, Las Vegas, United States. Speakers: Judi Vensak, Director, Field Medical.

CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA

CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted the company seven years of orphan-drug exclusivity for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks. HAEGARDA was approved by the FDA on June 22, 2017 for routine prophylaxis to prevent HAE attacks in adolescent and adult patients, and marketing exclusivity will continue through June 22, 2024. HAEGARDA is a plasma-derived concentrate of C1-INH that is self-administered twice weekly subcutaneously. Subcutaneous administration of C1-INH builds and maintains a steady-state level of functional C1-INH activity and offers patients ease of use by eliminating the need for venous access, including ports. In addition, HAEGARDA had a reduction in the use of rescue medication by a median of greater than 99% relative to placebo.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

August 28, 2017
Calimmune, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CSL Behring LLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at